Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

<p>DEG Table for R vs NR (mRNAseq)</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Gregory L. Beatty (15087193) (author)
Andere auteurs:	Devora Delman (15129986) (author), Jiayi Yu (16743347) (author), Mingen Liu (16743350) (author), Joey H. Li (15129989) (author), Liti Zhang (16743353) (author), Jae W. Lee (16743356) (author), Renee B. Chang (15129983) (author), Nathan Bahary (16743359) (author), Eugene P. Kennedy (16743362) (author), Andrea Wang-Gillam (15049923) (author), Gabriela R. Rossi (16743365) (author), Ignacio Garrido-Laguna (15131889) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Chemotherapy Gastrointestinal Cancers Pancreatic cancer Translational Research
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
door: Gregory L. Beatty (15087193)
Gepubliceerd in: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
door: Jiachun Su (16990970)
Gepubliceerd in: (2025)

Image 9_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 8_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 6_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 7_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 4_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 5_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Image 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Table 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Table 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Table 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
door: Xiangjun Wang (2522917)
Gepubliceerd in: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
door: Yan Zhou (15053225)
Gepubliceerd in: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S4 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S5 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S6 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S7 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Movie S8 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
door: Fang Wei (15057172)
Gepubliceerd in: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
door: Elizabeth R. Tucker (15053624)
Gepubliceerd in: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
door: Dwight H. Owen (15034782)
Gepubliceerd in: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
door: Dwight H. Owen (15034782)
Gepubliceerd in: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
door: Dwight H. Owen (15034782)
Gepubliceerd in: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
door: Dwight H. Owen (15034782)
Gepubliceerd in: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
door: Dwight H. Owen (15034782)
Gepubliceerd in: (2025)

Supplementary Table 1 from Comprehensive DNA Methylation Analysis Indicates That Pancreatic Intraepithelial Neoplasia Lesions Are Acinar-Derived and Epigenetically Primed for Carcinogenesis
door: Emily K.W. Lo (15618846)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l